The global Sevoflurane market size was valued at US$ 1230 million in 2024 and is forecast to a readjusted size of USD 1564 million by 2031 with a CAGR of 3.5% during review period.
Sevoflurane is a volatile anesthetic commonly used for induction and maintenance of general anesthesia during surgical procedures. It is favored for its rapid onset and offset of action, making it ideal for both adults and pediatric patients. Sevoflurane is typically inhaled and works by depressing the central nervous system, leading to a reversible loss of consciousness and sensation. Its minimal airway irritation and low blood solubility contribute to smoother anesthesia induction and quicker recovery times compared to other anesthetics. Sevoflurane is widely used due to its safety profile and ease of administration.
The key driver for the Sevoflurane market is the increasing number of surgeries worldwide, driven by the aging population and the rising prevalence of chronic conditions requiring surgical intervention. Sevoflurane is highly preferred due to its rapid onset and recovery, making it ideal for both pediatric and adult patients, particularly in outpatient surgeries. Technological advancements in anesthesia delivery systems and the growing demand for minimally invasive procedures have also contributed to the rising adoption of Sevoflurane in clinical settings. Furthermore, the safety and effectiveness of Sevoflurane in maintaining stable cardiovascular function during anesthesia have enhanced its demand.
One of the main challenges in the Sevoflurane market is its high cost compared to other anesthetic agents, which can limit its accessibility in low- and middle-income regions. Additionally, environmental concerns regarding the use of volatile anesthetics like Sevoflurane, which contribute to greenhouse gas emissions, have led to increased scrutiny and calls for more sustainable alternatives. Regulatory restrictions and the availability of generic alternatives may further impact the market growth, as healthcare providers seek more cost-effective or environmentally friendly options.
This report is a detailed and comprehensive analysis for global Sevoflurane market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Sevoflurane market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Sevoflurane market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Sevoflurane market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Sevoflurane market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Sevoflurane
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Sevoflurane market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Hengrui, Baxter, Maruishi, AbbVie, Piramal, Viatris, PT Novell Pharmaceutical, Lunan Pharma, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 Segmentation
Sevoflurane market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Generic Drug
Original Drug
麻豆原创 segment by Application
Hospital
Clinics
Other
Major players covered
Hengrui
Baxter
Maruishi
AbbVie
Piramal
Viatris
PT Novell Pharmaceutical
Lunan Pharma
麻豆原创 segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Sevoflurane product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Sevoflurane, with price, sales quantity, revenue, and global market share of Sevoflurane from 2020 to 2025.
Chapter 3, the Sevoflurane competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Sevoflurane breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Sevoflurane market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Sevoflurane.
Chapter 14 and 15, to describe Sevoflurane sales channel, distributors, customers, research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 麻豆原创 Analysis by Type
1.3.1 Overview: Global Sevoflurane Consumption Value by Type: 2020 Versus 2024 Versus 2031
1.3.2 Generic Drug
1.3.3 Original Drug
1.4 麻豆原创 Analysis by Application
1.4.1 Overview: Global Sevoflurane Consumption Value by Application: 2020 Versus 2024 Versus 2031
1.4.2 Hospital
1.4.3 Clinics
1.4.4 Other
1.5 Global Sevoflurane 麻豆原创 Size & Forecast
1.5.1 Global Sevoflurane Consumption Value (2020 & 2024 & 2031)
1.5.2 Global Sevoflurane Sales Quantity (2020-2031)
1.5.3 Global Sevoflurane Average Price (2020-2031)
2 Manufacturers Profiles
2.1 Hengrui
2.1.1 Hengrui Details
2.1.2 Hengrui Major Business
2.1.3 Hengrui Sevoflurane Product and Services
2.1.4 Hengrui Sevoflurane Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 Hengrui Recent Developments/Updates
2.2 Baxter
2.2.1 Baxter Details
2.2.2 Baxter Major Business
2.2.3 Baxter Sevoflurane Product and Services
2.2.4 Baxter Sevoflurane Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 Baxter Recent Developments/Updates
2.3 Maruishi
2.3.1 Maruishi Details
2.3.2 Maruishi Major Business
2.3.3 Maruishi Sevoflurane Product and Services
2.3.4 Maruishi Sevoflurane Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 Maruishi Recent Developments/Updates
2.4 AbbVie
2.4.1 AbbVie Details
2.4.2 AbbVie Major Business
2.4.3 AbbVie Sevoflurane Product and Services
2.4.4 AbbVie Sevoflurane Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 AbbVie Recent Developments/Updates
2.5 Piramal
2.5.1 Piramal Details
2.5.2 Piramal Major Business
2.5.3 Piramal Sevoflurane Product and Services
2.5.4 Piramal Sevoflurane Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 Piramal Recent Developments/Updates
2.6 Viatris
2.6.1 Viatris Details
2.6.2 Viatris Major Business
2.6.3 Viatris Sevoflurane Product and Services
2.6.4 Viatris Sevoflurane Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 Viatris Recent Developments/Updates
2.7 PT Novell Pharmaceutical
2.7.1 PT Novell Pharmaceutical Details
2.7.2 PT Novell Pharmaceutical Major Business
2.7.3 PT Novell Pharmaceutical Sevoflurane Product and Services
2.7.4 PT Novell Pharmaceutical Sevoflurane Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 PT Novell Pharmaceutical Recent Developments/Updates
2.8 Lunan Pharma
2.8.1 Lunan Pharma Details
2.8.2 Lunan Pharma Major Business
2.8.3 Lunan Pharma Sevoflurane Product and Services
2.8.4 Lunan Pharma Sevoflurane Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 Lunan Pharma Recent Developments/Updates
3 Competitive Environment: Sevoflurane by Manufacturer
3.1 Global Sevoflurane Sales Quantity by Manufacturer (2020-2025)
3.2 Global Sevoflurane Revenue by Manufacturer (2020-2025)
3.3 Global Sevoflurane Average Price by Manufacturer (2020-2025)
3.4 麻豆原创 Share Analysis (2024)
3.4.1 Producer Shipments of Sevoflurane by Manufacturer Revenue ($MM) and 麻豆原创 Share (%): 2024
3.4.2 Top 3 Sevoflurane Manufacturer 麻豆原创 Share in 2024
3.4.3 Top 6 Sevoflurane Manufacturer 麻豆原创 Share in 2024
3.5 Sevoflurane 麻豆原创: Overall Company Footprint Analysis
3.5.1 Sevoflurane 麻豆原创: Region Footprint
3.5.2 Sevoflurane 麻豆原创: Company Product Type Footprint
3.5.3 Sevoflurane 麻豆原创: Company Product Application Footprint
3.6 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Sevoflurane 麻豆原创 Size by Region
4.1.1 Global Sevoflurane Sales Quantity by Region (2020-2031)
4.1.2 Global Sevoflurane Consumption Value by Region (2020-2031)
4.1.3 Global Sevoflurane Average Price by Region (2020-2031)
4.2 North America Sevoflurane Consumption Value (2020-2031)
4.3 Europe Sevoflurane Consumption Value (2020-2031)
4.4 Asia-Pacific Sevoflurane Consumption Value (2020-2031)
4.5 South America Sevoflurane Consumption Value (2020-2031)
4.6 Middle East & Africa Sevoflurane Consumption Value (2020-2031)
5 麻豆原创 Segment by Type
5.1 Global Sevoflurane Sales Quantity by Type (2020-2031)
5.2 Global Sevoflurane Consumption Value by Type (2020-2031)
5.3 Global Sevoflurane Average Price by Type (2020-2031)
6 麻豆原创 Segment by Application
6.1 Global Sevoflurane Sales Quantity by Application (2020-2031)
6.2 Global Sevoflurane Consumption Value by Application (2020-2031)
6.3 Global Sevoflurane Average Price by Application (2020-2031)
7 North America
7.1 North America Sevoflurane Sales Quantity by Type (2020-2031)
7.2 North America Sevoflurane Sales Quantity by Application (2020-2031)
7.3 North America Sevoflurane 麻豆原创 Size by Country
7.3.1 North America Sevoflurane Sales Quantity by Country (2020-2031)
7.3.2 North America Sevoflurane Consumption Value by Country (2020-2031)
7.3.3 United States 麻豆原创 Size and Forecast (2020-2031)
7.3.4 Canada 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Mexico 麻豆原创 Size and Forecast (2020-2031)
8 Europe
8.1 Europe Sevoflurane Sales Quantity by Type (2020-2031)
8.2 Europe Sevoflurane Sales Quantity by Application (2020-2031)
8.3 Europe Sevoflurane 麻豆原创 Size by Country
8.3.1 Europe Sevoflurane Sales Quantity by Country (2020-2031)
8.3.2 Europe Sevoflurane Consumption Value by Country (2020-2031)
8.3.3 Germany 麻豆原创 Size and Forecast (2020-2031)
8.3.4 France 麻豆原创 Size and Forecast (2020-2031)
8.3.5 United Kingdom 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Russia 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Italy 麻豆原创 Size and Forecast (2020-2031)
9 Asia-Pacific
9.1 Asia-Pacific Sevoflurane Sales Quantity by Type (2020-2031)
9.2 Asia-Pacific Sevoflurane Sales Quantity by Application (2020-2031)
9.3 Asia-Pacific Sevoflurane 麻豆原创 Size by Region
9.3.1 Asia-Pacific Sevoflurane Sales Quantity by Region (2020-2031)
9.3.2 Asia-Pacific Sevoflurane Consumption Value by Region (2020-2031)
9.3.3 China 麻豆原创 Size and Forecast (2020-2031)
9.3.4 Japan 麻豆原创 Size and Forecast (2020-2031)
9.3.5 South Korea 麻豆原创 Size and Forecast (2020-2031)
9.3.6 India 麻豆原创 Size and Forecast (2020-2031)
9.3.7 Southeast Asia 麻豆原创 Size and Forecast (2020-2031)
9.3.8 Australia 麻豆原创 Size and Forecast (2020-2031)
10 South America
10.1 South America Sevoflurane Sales Quantity by Type (2020-2031)
10.2 South America Sevoflurane Sales Quantity by Application (2020-2031)
10.3 South America Sevoflurane 麻豆原创 Size by Country
10.3.1 South America Sevoflurane Sales Quantity by Country (2020-2031)
10.3.2 South America Sevoflurane Consumption Value by Country (2020-2031)
10.3.3 Brazil 麻豆原创 Size and Forecast (2020-2031)
10.3.4 Argentina 麻豆原创 Size and Forecast (2020-2031)
11 Middle East & Africa
11.1 Middle East & Africa Sevoflurane Sales Quantity by Type (2020-2031)
11.2 Middle East & Africa Sevoflurane Sales Quantity by Application (2020-2031)
11.3 Middle East & Africa Sevoflurane 麻豆原创 Size by Country
11.3.1 Middle East & Africa Sevoflurane Sales Quantity by Country (2020-2031)
11.3.2 Middle East & Africa Sevoflurane Consumption Value by Country (2020-2031)
11.3.3 Turkey 麻豆原创 Size and Forecast (2020-2031)
11.3.4 Egypt 麻豆原创 Size and Forecast (2020-2031)
11.3.5 Saudi Arabia 麻豆原创 Size and Forecast (2020-2031)
11.3.6 South Africa 麻豆原创 Size and Forecast (2020-2031)
12 麻豆原创 Dynamics
12.1 Sevoflurane 麻豆原创 Drivers
12.2 Sevoflurane 麻豆原创 Restraints
12.3 Sevoflurane Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of Sevoflurane and Key Manufacturers
13.2 Manufacturing Costs Percentage of Sevoflurane
13.3 Sevoflurane Production Process
13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Sevoflurane Typical Distributors
14.3 Sevoflurane Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
Hengrui
Baxter
Maruishi
AbbVie
Piramal
Viatris
PT Novell Pharmaceutical
Lunan Pharma
听
听
*If Applicable.
